Expands Medicare Access in Massive MAHA Victory
By Michael Phillips – The Thunder Report
Washington, D.C. – November 6, 2025
In a bombshell Oval Office announcement that electrified the nation, President Donald J. Trump today unveiled historic agreements with pharmaceutical powerhouses Eli Lilly and Novo Nordisk, slashing prices of blockbuster GLP-1 weight-loss drugs like Wegovy and Zepbound to as low as $149 per month for millions of Americans.
Flanked by Eli Lilly CEO David A. Ricks and Novo Nordisk CEO Maziar Mike Doustdar, Trump hailed the pacts as a “promise made, promise kept” in his crusade to dismantle Big Pharma’s pricing stranglehold and supercharge the Make America Healthy Again (MAHA) initiative.
“Today, I’m thrilled to announce that the world’s two largest pharmaceutical manufacturers, Eli Lilly and Novo Nordisk, have agreed to offer their most popular GLP-1 weight-loss drug — I call it the fat drug, remember — at drastic discounts,” Trump declared, his voice booming through the White House as cameras rolled live on Fox News.
The Deals: Affordability Meets Access
Forged under Trump’s revived Most Favored Nation (MFN) executive order, the deals tie U.S. drug prices to the lowest rates paid abroad, while unlocking unprecedented federal coverage for obesity treatment — a seismic policy shift in a nation where 42% of adults battle obesity.
- New prices: Starting doses of GLP-1s drop from over $1,000/month to $149 for pills and $245 for injectables, available immediately via the forthcoming TrumpRx direct-to-consumer platform.
- Medicare coverage: Seniors (roughly 3.4 million beneficiaries) will pay just $50 copays for approved uses.
- Medicaid expansion: States may opt in for coverage starting mid-2026.
“This isn’t just about pills—it’s a reset for America’s health,” said HHS Secretary Robert F. Kennedy Jr., who joined Trump after months of negotiations. RFK Jr., once skeptical of GLP-1s, called them a “bridge for patients who’ve exhausted lifestyle fixes,” linking the rollout to MAHA’s broader war on processed foods and junk nutrition.
The pacts also mandate MFN pricing across both companies’ full catalogs on TrumpRx and commit a combined $37 billion in U.S. manufacturing investments — $27B from Lilly and $10B from Novo — to onshore production and avoid tariffs.
Novo’s Doustdar called it “a win-win for affordable access,” while Ricks added: “We’re aligning with President Trump’s vision to make these life-changing therapies reachable for all.”
A Press Conference Packed with Fireworks
As thunder rumbled outside the White House — mirroring the storm inside pharma boardrooms — Trump’s team delivered a fiery follow-up presser.
CMS Administrator Dr. Mehmet Oz called the move “a game-changer for four million low-income families,” estimating $20 billion in annual healthcare savings from reduced diabetes and heart-disease comorbidities.
Press Secretary Karoline Leavitt hit X with:
“Promise Made. Promise Kept. President Trump is lowering drug costs for the American people.”
X erupted:
“Trump just KO’d Big Pharma — $149 Ozempic? MAHA is real!” cheered one user.
Skeptics warned of “long-term side effect black holes” amid ongoing lawsuits, but markets roared anyway — Lilly stock up 4%, Novo up 6%, betting on explosive demand in a $100B obesity market.
Backlash and the Bigger Battle
Democrats derided the plan as a “corporate handout in discount wrapping,” citing a projected $35–40 billion decade-long cost, while PhRMA blasted the MFN rule as “imported socialism.”
RFK Jr. fired back:
“We’re not subsidizing addiction — we’re arming Americans against it.”
The move caps a whirlwind year in Trump’s MAHA offensive, which began with MFN-driven Pfizer and AstraZeneca deals earlier in 2025, saving billions in Medicaid spending.
Today’s announcement cements obesity — not just price gouging — as the new battleground for Trump’s second-term health revolution.
“We’re gonna make America slim again,” Trump vowed, grinning as applause thundered through the East Room.
Implementation hurdles remain — FDA approvals, state buy-ins, and congressional funding fights — but for 100 million+ Americans struggling with obesity, this may be the dawn of a healthier horizon.
Discover more from RIPTIDE
Subscribe to get the latest posts sent to your email.
